Prions are the infectious agents responsible for prion diseases, which appear to be composed exclusively by the misfolded prion protein (PrPSc). Disease is transmitted by the autocatalytic propagation of PrPSc misfolding at the expense of the normal prion protein. The biggest challenge of the prion hypothesis has been to explain the molecular mechanism by which prions can exist as different strains, producing diseases with distinguishable characteristics. Here, we show that PrPSc generated in vitro by protein misfolding cyclic amplification from five different mouse prion strains maintains the strain‐specific properties. Inoculation of wild‐type mice with in vitro‐generated PrPSc caused a disease with indistinguishable incubation times as well as neuropathological and biochemical characteristics as the parental strains. Biochemical features were also maintained upon replication of four human prion strains. These results provide additional support for the prion hypothesis and indicate that strain characteristics can be faithfully propagated in the absence of living cells, suggesting that strain variation is dependent on PrPSc properties.
Prions are the unconventional infectious agents responsible for prion diseases, a group of fatal, neurodegenerative disorders, including Creutzfeldt‐Jakob disease (CJD) in humans, scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle and chronic wasting disease in deer, among others (Collinge, 2001). The infectious agent appears to be composed exclusively by a misfolded version of the prion protein (PrPSc) that replicates in the body in the absence of nucleic acids by inducing the misfolding of the cellular prion protein (PrPC) (Prusiner, 1998). Although recent studies showing in vitro generation of infectious material by inducing or amplifying PrP misfolding have provided strong support for the prion hypothesis (Legname et al, 2004; Castilla et al, 2005; Deleault et al, 2007), it remains still highly controversial (Somerville, 2000; Chesebro, 2003; Soto and Castilla, 2004; Weissmann, 2004).
One of the main difficulties of the prion hypothesis has been to provide a molecular explanation for the prion strain phenomenon (Chesebro, 1998; Somerville, 2002; Aguzzi et al, 2007; Morales et al, 2007). Most TSEs are known to exhibit various ‘strains’ characterized by differences in incubation periods, clinical symptoms and biochemical and neuropathological features (Bruce, 2003; Aguzzi et al, 2007; Morales et al, 2007). In infectious diseases associated with conventional microbial agents (virus, bacteria and so on), different strains arise from mutations or polymorphisms in the genetic make‐up of the agent. To reconcile the infectious agent composed exclusively of a protein with the strain phenomenon, it has been proposed that the strain characteristics are dependent on slightly different conformation or aggregation states of PrPSc, which can faithfully replicate at expenses of the host PrPC (Telling et al, 1996; Prusiner, 1998; Morales et al, 2007). These different folding states of PrPSc may lead to selectively targeting distinct brain regions producing the diverse neuropathological alterations and clinical symptoms characteristic of prion strains. Support for this concept came from various studies showing that PrPSc from different strains have noticeable distinct biochemical properties and secondary structures (Caughey et al, 1998; Safar et al, 1998). However, up to now it is not known whether such differences are the cause or simply another manifestation of the prion strain phenomenon. Furthermore, the concept that a single protein can provide the conformational flexibility and the mechanism to propagate diverse strains is very intriguing and unprecedented. The definitive proof that the strain phenomenon is encoded in the PrPSc structure would be to reproduce in the test tube the folding of PrPSc associated with different strains and to show that the in vitro‐generated infectious proteins maintain the in vivo strain characteristics. Important findings in this direction have been obtained for yeast prions, which are a group of ‘infectious proteins’ that behave as non‐Mendelian genetic elements and transmit biological information in the absence of nucleic acid (Wickner et al, 1995). Compelling evidences have provided support for the prion nature of several yeast proteins, including Sup35p, Ure2p, Rnq1 (Uptain and Lindquist, 2002; Chien et al, 2004; Wickner et al, 2004). Recent studies showed that bacterially produced N‐terminal fragments of Sup35p and Ure2p when transformed into amyloid fibrils were able to propagate the prion phenotype to yeast cells (King and Diaz‐Avalos, 2004; Tanaka et al, 2004; Brachmann et al, 2005). Remarkably, infection of yeasts with recombinant Sup35 folded in different conformations led to the generation of distinct prion strains in vivo (Tanaka et al, 2004; Brachmann et al, 2005), indicating that structural differences in the infectious protein determine prion strain variation.
On the basis of theoretical considerations about the mechanisms of prion conversion, we have developed a strategy to reproduce PrPSc replication in vitro with a similar efficiency to the in vivo process, but with accelerated kinetics (Saborio et al, 2001). This system called PMCA (protein misfolding cyclic amplification) was designed to mimic PrPSc autocatalytic replication. In a cyclic manner, conceptually analogous to PCR cycling, a minute quantity of PrPSc (as little as one single particle) is incubated with excess PrPC to enlarge the PrPSc aggregates that are then sonicated to generate multiple smaller units for the continued formation of new PrPSc (Saborio et al, 2001; Saá et al, 2006). PMCA confirms a central facet of the prion hypothesis, which is that prion replication is an autocatalytic process and that newly produced PrPSc can further propagate the protein misfolding (Soto et al, 2002). We have previously reported proof‐of‐concept experiments in which the technology was applied to replicate the misfolded protein from diverse species (Soto et al, 2005). The newly generated protein exhibits the same biochemical, biological and structural properties as brain‐derived PrPSc and is infectious to wild‐type animals, producing a disease with similar characteristics as the illness produced by brain‐isolated prions (Castilla et al, 2005).
The main goal of this study was to assess whether the specific biological, biochemical and infectious properties of distinct prion strains can be maintained after in vitro replication. For this purpose, we propagated five different mouse and four distinct human prion strains in vitro by PMCA using as substrate PrPC from the same normal mouse or human transgenic mouse brain extract, respectively. PrPSc associated with each strain was serially diluted and replicated in vitro to produce misfolded protein free from brain PrPSc inoculum. In vitro‐generated PrPSc maintains the strain‐specific biochemical properties and more importantly upon injection into wild‐type mice produced a disease with indistinguishable characteristics as the parental strain. These results suggest that all strain‐associated features can be maintained by cell‐free formed PrPSc, suggesting that the prion strain phenomenon is enciphered on the characteristics of the misfolded prion protein.
In vitro propagation of prion strains
To analyse whether in vitro replication of prion strains faithfully propagates the biochemical properties of PrPSc, we used five well‐characterized strains from mouse and four from human. As many as 20 different prion strains have been identified in mouse after inoculation of animals with prions from diverse origins (Fraser and Dickinson, 1973; Kimberlin, 1976; Bruce, 2003). Four of the mouse strains used in this study (RML, 139A, ME7 and 79A) are originated from different scrapie sources and have been adapted into mouse by repetitive passages. These mouse‐adapted scrapie strains have been shown to have some differences in brain lesion profiles, incubation times in diverse mouse backgrounds and susceptibility to PrP polymorphisms (Fraser and Dickinson, 1973; Bruce et al, 1991). On the other hand, 301C is a strain originated from cattle BSE, which has been serially passed in wild‐type mice (Bruce et al, 2002). Mouse brain homogenates from animals experimentally infected with these different strains were diluted 10‐fold into 10% normal mice brain homogenate. Samples were either immediately frozen or subjected to 96 PMCA cycles. The amplified samples were further diluted 10‐fold and a new round of 96 PMCA cycles was carried out. This procedure of serial dilution/amplification was repeated many times to reach a 10−20 total dilution of the brain infectious material and these samples were used in the studies described below. In our estimation, this degree of dilution is at least 1 million‐fold higher than what is necessary to remove the last molecule of PrPSc coming from the brain inoculum and at least a trillion (1012)‐fold more than the last infectious dilution (Castilla et al, 2005). As determined by western blot after proteinase K (PK) digestion, a protease‐resistant product was observed in all these amplifications, which remained constant despite the dilutions (data not shown). These results suggest that PrPSc is being produced in vitro and the newly generated PrPSc is capable of sustaining replication, as demonstrated before for hamster prions (Castilla et al, 2005). We conclude from these results that PMCA enables an infinite replication of PrPSc in vitro and the large dilution performed (10−20) guarantees that the sample contains exclusively in vitro‐produced misfolded protein. Assessment of the western blot profile after PK treatment for PMCA‐generated PrPSc compared with in vivo‐produced misfolded protein from each strain shows that both the proportion of glycoforms and the electrophoretic mobility were conserved after in vitro propagation (Figure 1). As shown in Figure 1A, the scrapie‐derived mouse strains (RML, ME7, 139A and 79A) have a glycoform distribution dominated by the mono‐glycosylated form, whereas in 301C PrPSc the most abundant isoform is the di‐glycosylated species. Importantly, the glycoform ratio in PMCA‐generated PrPSc was very similar to the brain‐derived protein. The relative migration of the protein in gel electrophoresis was also strikingly similar, which is easily observed upon deglycosylation when comparing only the size of the non‐glycosylated protein (Figure 1B). PrPSc from scrapie‐adapted mouse strains migrate with an estimated molecular weight of 21 kDa, whereas the bovine‐derived 301C protein exhibits a ∼19 kDa size. These findings indicate that the PK cleavage site in PrPSc generated in vitro by PMCA is similar to the site in which the protein obtained from the brain of sick animals is cleaved by this enzyme. This is important because differences in proteolytic cleavage likely reflect distinct foldings of the protein in diverse strains (Marsh and Bessen, 1994; Collinge et al, 1996; Chen et al, 2000; Gretzschel et al, 2005). It is noteworthy that the PrPC substrate used for conversion was the same for all strains and thus the molecular characteristics of PrPSc in the inoculum are responsible for the propagation of the different biochemical properties of the protein. A control experiment in which samples of brain homogenate from 10 different healthy mice were serially diluted into itself and subjected to the same number of PMCA cycles as described above, but in the absence of PrPSc inoculum, did not show any protease‐resistant PrP under the conditions used (data not shown). Although we have been able to generate infectious PrPSc ‘de novo’ (without the addition of brain PrPSc) recently, this requires modification of some PMCA parameters (paper under review) and under standard PMCA conditions, as those used in this study, spontaneous generation of infectious material does not occur. These findings suggest that de novo formation of PrPSc can be experimentally distinguished from replication of pre‐formed PrPSc, indicating that the biochemical, conformational or stability properties of the PrP structures involved in both processes are probably different.
To further assess whether the PrPSc features are maintained after in vitro replication by PMCA, we tested four different human strains with well‐established differences in the biochemical properties of PrPSc (Gambetti et al, 2003). The samples came from patients affected by vCJD, and three distinct types of sCJD (types MM1, MM2 and VV2). PrPSc from vCJD and sCJD types MM1 and MM2 was amplified using as substrate transgenic mice brain expressing human PrP with MM genotype at position 129 and the sCJD type VV2 was amplified using transgenic mice expressing VV PrPC. Little or no amplification was obtained when PrPSc and PrPC have different polymorphism at position 129. Samples were subjected to the same scheme of serial PMCA and dilutions as described in the mouse experiment above to dilute out the PrPSc inocula used to trigger the reaction. Comparison of the glycoform proportion (Figure 1C) and the electrophoretic mobility after PK and deglycosylation (Figure 1D) between brain‐derived and PMCA‐generated PrPSc for each strains clearly show that the biochemical features were maintained upon in vitro propagation. Unseeded PMCA reactions of healthy human PrP transgenic mice brain homogenates did not show ‘de novo’ PrPSc generation under the conditions tested (data not shown).
In vitro‐generated PrPSc maintains strain‐specific infectivity properties
To determine the infectious capability of in vitro‐generated PrPSc and to assess the preservation of strain characteristics, we inoculated the five mouse strains into wild‐type animals. Groups of mice were injected intracerebrally (i.c.) with a similar quantity of either brain‐derived or PMCA‐produced PK‐resistant PrPSc. Appearance of clinical signs was monitored over time as described in Materials and methods. The first alterations observed were rough coat initially in the neck, which then extended to the lower back. This was followed by hunchback, urogenital lesions, cachexia and ataxia. Unfortunately, no substantial differences in clinical signs are evident among these strains other than the observation that 301C has a more severe urogenital damage, including abundant pus secretion. Nevertheless, the time of appearance of clinical alterations (Table I), and the type and severity of the signs were very similar in the animals inoculated with infectious material obtained from sick brain or produced in vitro by PMCA. None of the animals inoculated with normal brain homogenate subjected or not to the same regimen of serial PMCA amplification showed disease signs up to 500 days post‐inoculation (Table I). Interestingly, in none of these experiments we found a significant delay on the incubation time for the in vitro‐generated prions compared with the in vivo‐produced infectious agent, as we reported earlier in our experiments with hamster 263K scrapie prions (Castilla et al, 2005). These findings indicate that the infectivity associated with PMCA‐generated PrPSc was the same as for misfolded protein obtained from the brain in all the mouse strains studied. A second passage of the in vitro‐generated infectious material showed the same incubation periods, suggesting that the infectious agent was stable (Table I). Similar results were obtained when the material was inoculated intraperitoneally, albeit with longer incubation times (Data not shown). Statistical analysis of the incubation periods showed that the differences between the brain‐derived material or PMCA‐generated infectivity (first and second passages) were not significant for any of the strains studied (see P‐values in Table I). Conversely, the incubation times for 301C were highly significantly different from all the other strains, as assessed by two‐way ANOVA (P<0.001). The differences between the ovine‐derived strains are nonsignificant, except for 139A versus 79A (P=0.0031).
Besides incubation time, one of the main differences among prion strains is the distribution and severity of damage in distinct regions of the brain (Fraser and Dickinson, 1973). To assess whether in vitro‐generated infectious agent maintains the neuropathological signature of the parental strain, we evaluated the degree of vacuolation in various brain areas of infected animals, as described in Materials and methods. The profile of spongiform degeneration obtained for each strain using brain‐derived or PMCA‐generated material was statistically undistinguishable (Figures 2 and 3), indicating again that in vitro propagation of prions maintains the strains properties. As shown in Figure 3, statistical analyses of the brain lesion profile enable to differentiate three groups of strains: 301C, 79A and the other three ovine‐derived strains (RML, 139A, ME7), which are not significantly different in their pattern of vacuolation. 301C‐infected mice exhibit large extent of spongiosis in medulla and hippocampus, medium degree of damage in colliculus, hypothalamus and thalamus and very little vacuolation in cerebellum and cortex (Figures 2 and 3). On the other hand, the ovine strains RML, 139A and ME7 have a large extent of spongiform degeneration in cerebellum and only little damage in colliculus and hypothalamus. Finally, the 79A strain produces a more even pattern of vacuolation in the eight brain areas studied. These neuropathological differences were also observed in the animals inoculated with PMCA‐generated PrPSc. The neuropathological similarities produced by inoculation of in vitro‐ and in vivo‐produced PrPSc were also evident by immunohistochemical staining with antibodies against PrP and GFAP (a marker for reactive astrocytes) (Figure 4).
Another difference among strains widely exploited to characterize and differentiate them is the biochemical properties of PrPSc accumulated in the brain. PrPSc associated with different strains can be distinguished biochemically by its glycosylation profile, PK cleavage, susceptibility to protease digestion, resistance to denaturation and secondary structure (Bessen and Marsh, 1992; Caughey et al, 1998; Safar et al, 1998; Hill et al, 2003). To assess some of these biochemical properties, we studied PrPSc from the brain of animals killed after showing signs of the disease produced by inoculation with different strains of infectious material generated in vitro by PMCA or obtained from the brain of sick mice. Comparison of the PrPSc western blot profile after PK digestion showed that both the glycoform distribution and the electrophoretic mobility are similar for each strain regardless of whether the infectious material was derived from brain or generated by PMCA (Figure 5A and B). As described before, PrPSc in the mouse strains originated from scrapie have a glycoform distribution dominated by the mono‐glycosylated form, whereas in PrPSc from the 301C strain the most abundant isoform is the di‐glycosylated form (Figure 5A). As the PrPC used as substrate for conversion was the same for all strains, these results indicate that PrPSc from distinct strains can preferentially recruit and convert PrPC with particular glycosylation types. Importantly, comparing the results shown in Figures 1A and 5A, it is possible to conclude that the glycoform distribution of PrPSc is maintained in vitro and in vivo and that the PMCA‐generated PrPSc from each strain can further propagate these biochemical characteristics when inoculated into wild‐type mice. Finally, we studied the susceptibility of the misfolded protein from different strains to PK degradation. Partial resistance to proteolysis is one of the typical features of PrPSc and data suggest that the misfolded proteins associated with diverse strains exhibit different susceptibility to PK digestion (Bessen and Marsh, 1992). To compare the protease resistance profile, similar quantities of PrPSc from the brain of animals inoculated with various strains of either brain‐derived or PMCA‐generated prions were treated for 60 min with 125, 250, 500, 750 and 1500 μg/ml of PK. The susceptibility of 301C PrPSc to PK degradation is dramatically different when compared with the ovine‐derived strains. Figure 6 shows two of the ovine strains (139A and 79A), but similar results were obtained with the other strains used in this study (data not shown). Much larger concentrations of PK are required to degrade PrPSc from 301C than 139A or 79A strains as shown in the densitometric evaluation of the western blots from three independent experiments for each sample (graphs in Figure 6). Importantly, PrPSc from animals inoculated with in vitro‐generated material exhibits the same characteristics of PK resistance.
The prion hypothesis proposes that the infectious agent responsible for TSE transmission is a misfolded protein that has the unique capability to propagate the disease by transmitting its abnormal folding properties (Prusiner, 1998). Undoubtedly, the biggest challenge of the ‘protein‐only’ hypothesis has been to provide a credible molecular explanation to the prion strain phenomenon (Chesebro, 1998; Somerville, 2002; Aguzzi et al, 2007; Morales et al, 2007). Prions as conventional infectious agents exist in different forms to produce diseases with distinct characteristics (Bruce, 2003; Aguzzi et al, 2007; Morales et al, 2007). In traditional infectious diseases, strains are determined by polymorphisms or mutations in the nucleic acid of the agent. However, prions do not appear to contain nucleic acids. Therefore, a key question in the field has been to understand how a single protein can encode the diversity of information needed to produce and propagate many strains. The proposal that strains are dependent on differences in the folding and aggregation stage of the prion protein that can be faithfully propagated in the animal to determine diverse disease phenotypes has been taken with scepticism (Farquhar et al, 1998). It is hard to reconcile the last 20 years of knowledge on protein folding with the idea that a single protein can adopt dozens of stable alternative structures that can imprint their unique folding into the natively folded normal prion protein. An alternative hypothesis, termed the ‘unified theory’, has been proposed to suggest that although PrPSc is the infectious agent, the strain diversity is dependent on the presence of an ancillary cofactor, likely a nucleic acid (Weissmann, 1991). Although many efforts to identify such nucleic acid cofactor have failed (Kellings et al, 1994; Safar et al, 2005), the consensus hypothesis is still considered a plausible explanation for the strain phenomenon. One of the strongest arguments against the idea that strains are enciphered exclusively in the PrPSc folding is that so far the strain‐specific infectious properties have not been generated or propagated in vitro in a cell‐free system.
In a previous study, we successfully generated and propagated infectious prions in vitro using the PMCA technology to autocatalytically replicate PrPSc in a cell‐free system (Castilla et al, 2005). We showed that hamster PrPSc could be maintained indefinitely replicating even in the absence of any molecule of brain‐derived PrPSc. Inoculation of wild‐type hamsters with in vitro‐produced PrPSc led to a scrapie disease similar to the illness produced by brain infectious material (Castilla et al, 2005). Subsequently, we showed that large amounts of infectious material can be generated from subinfectious quantities of sick hamster brain, equivalent to a single particle of PrPSc oligomers (Saá et al, 2006). These studies provided a strong proof in favor of the prion hypothesis, but did not address the important issue of prion strains, as only one strain of hamster PrPSc was used. Also, the in vitro‐generated infectious agent produced disease with a delay in the incubation period, and thus the possibility that strain characteristics were not maintained could not be ruled out. A report from Kretzschmar's group confirmed our results and using nitrocellulose immobilization experiments, showed that the delay on the disease onset was likely not due to a strain switch, but possibly to a different size proportion of PrPSc oligomers that changed their clearance rate (Weber et al, 2007). Our current study shows that infectious prions can be generated in vitro by serial replication of PrPSc misfolding in a different species as the previous experiments. Interestingly, in contrast to our previous report, the current study shows that inoculation with in vitro‐generated prions produced the same incubation time as in vivo‐derived infectious material. These findings further support the concept that PrPSc is the only component needed for infectivity and that in vitro‐produced prions are very similar to the agent generated in the brain of sick animals. Nevertheless, the most relevant result of the current study is the successful propagation of the PrPSc biochemical properties of five different mouse prion strains and four human strains. Furthermore, the in vitro‐generated mouse prion strains were infectious to wild‐type mice conserving the typical properties of each strain. PrPSc from four mouse‐adapted scrapie strains (RML, 139A, ME7 and 79A) and one strain with cattle origin (301C) were propagated in vitro by 20 successive rounds of PMCA followed by dilutions to get rid of the initial inoculum progressively. After this procedure, the sick brain used as inoculum was diluted 1020‐folds, and therefore no molecules of PrPSc should be present unless they were generated in vitro during PMCA. Our data indicate that the strain‐specific differences in biochemical features of PrPSc (electrophoretical mobility and proportion of various glycoforms) associated with these strains were maintained after in vitro propagation, despite the fact that all the strains were replicated using the same source of PrPC substrate. More strikingly, when administered to wild‐type mice, in vitro‐generated PrPSc produced a disease in all cases with the same clinical features and incubation time as the parental strain. A detailed study of the neuropathological and biochemical characteristics of the brain of sick animals showed that in vitro‐generated prions produced the same profile of damage as in vivo‐derived infectious material. These results unequivocally demonstrate that strain characteristics were replicated in vitro by PMCA. Our findings provide additional support for the prion hypothesis and strongly argue that strain characteristics can be faithfully propagated in the absence of living cells, suggesting that strain variation is dependent on PrPSc biochemical changes.
Materials and methods
Five different mouse prion strains extensively adapted and characterized were used for these experiments. All strains were propagated several times in C57Bl6 wild‐type mice. Four human prion strains, associated with vCJD or sCJD (types MM1, MM2 and VV2), were obtained from patients with clinically and neuropathologically confirmed prion disease. Human PrPSc was replicated using brains of transgenic mice overexpressing human PrP with MM or VV genotype at position 129. Brains from healthy animals were extracted after mice were perfused with phosphate‐buffered saline (PBS) plus 5 mM EDTA. Brain homogenates (10%, w/v) were prepared in conversion buffer (PBS containing NaCl 150 mM, 1.0% Triton X‐100, 4 mM EDTA and the complete™ cocktail of protease inhibitors from Boehringer Mannheim, Mannheim, Germany). Brain from sick individuals were harvested and homogenized in PBS plus protease inhibitors. The samples were clarified by a brief, low‐speed centrifugation (2000 r.p.m. for 45 s) using an Eppendorf centrifuge (Hamburg, Germany), model 5414.
Serial replication of prions in vitro by PMCA
Aliquots of 10 μl of 10% brain homogenate from animals or humans infected with diverse strain were diluted into 90 μl of 10% normal brain homogenate and loaded onto 0.2‐ml PCR tubes. Tubes were positioned on an adaptor placed on the plate holder of a microsonicator (Misonix Model 3000, Farmingdale, NY) and programmed to perform cycles of 30‐min incubation at 37°C followed by a 20‐s pulse of sonication set at potency of 7. Samples were incubated, without shaking, immersed in the water of the sonicator bath. After a round of 96 cycles, a 10 μl aliquot of the amplified material was diluted into 90 μl of normal mouse brain homogenate and a new round of 96 PMCA cycles was performed. This procedure was repeated 19 times to reach a 10−20 final dilution of the initial sick brain homogenate. The detailed protocol for PMCA, including reagents, solutions and troubleshooting, has been published elsewhere (Castilla et al, 2004, 2006; Saá et al, 2004).
PK degradation assay
The standard procedure to digest PrPSc consists of subjecting the samples to incubation in the presence of PK (50 μg/ml) for 60 min with shaking at 37°C. The digestion was stopped by adding electrophoresis sample buffer and the protease‐resistant PrP was revealed by western blotting, as indicated below. To study the profile of PK sensitivity for in vitro‐ and in vivo‐generated PrPSc, the samples were incubated for 60 min at 37°C with different concentrations of PK ranging from 125 to 1500 μg/ml.
Proteins were fractionated by SDS‐polyacrylamide gel electrophoresis (SDS‐PAGE), electroblotted into nitrocellulose membrane and probed with 6H4 or 3F4 antibodies at a 1:5000 dilution for mouse and human samples, respectively. The immunoreactive bands were visualized by enhanced chemoluminescence assay (Amersham, Piscataway, NJ) using a UVP image analysis system. The immunoreactive bands were visualized by enhanced chemoluminescence assay (Amersham) using an UVP image analysis system. To assess the quantity of PrPSc in the western blot, densitometric analyses were done in triplicate.
Protein deglycosylation assay
PrPSc samples were first digested with PK as describe above. After addition of 10% sarkosyl, samples were centrifuged at 100 000 g for 1 h at 4°C, the supernatant was discarded and the pellet was resuspended in 100 μl of glycoprotein denaturing buffer (New England Biolabs, Beverly, MA) and incubated for 10 min at 100°C. Thereafter, 13 μl of 50 mM sodium phosphate, pH 7.5 containing 1% Nonidet P‐40 and 3 μl of peptide N‐glycosidase F (New England Biolabs) were added. Samples were incubated overnight at 37°C with shaking and the reaction was stopped by adding electrophoresis buffer and samples analysed by western blot as indicated before.
To inject the same quantity of PrPSc from each strain preparation, both in vitro generated and in vivo produced, the samples were compared by western blotting after PK digestion. To obtain a reliable and robust quantification, we ran several different dilutions of the sample in the same gel, to avoid artefacts due to saturation of the signal or to a too weak signal.
In vivo infectivity studies were done in C57Bl6 female mice purchased from Charles River. Animals were 4–6 weeks old at the time of inoculation. Anaesthetized animals were injected stereotaxically in the right hippocampus with 2 μl of the sample. The quantity of infectious material injected corresponds to the plateau portion of the incubation period (Supplementary Figure 1), therefore small differences in the amount of infectivity should not change incubation periods unless there are strain differences. To estimate the plateau of incubation period, we inoculated mice with different dilutions of infectious prions from distinct strains. The result indicates that dilutions lower than 150‐fold of sick brain homogenate are at plateau of infectivity (Supplementary Figure 1). In our experiment, the amount of infectious material corresponds to between 15‐ and 30‐fold dilution. The onset of clinical disease was measured by scoring the animals twice a week using the following scale: (1) normal animal; (2) roughcoat on limbs; (3) extensive roughcoat, hunckback and visible motor abnormalities; (4) urogenital lesions and (5) terminal stage of the disease in which the animal present cachexia and lies in the cage with little movement. Animals scoring level 5 were considered sick and were killed to avoid excessive pain using exposition to carbonic dioxide. Brains were extracted and analysed histologically. The right cerebral hemisphere was frozen and stored at −70°C for biochemical studies of PrPSc and the left hemisphere was used for histology analysis.
Brain tissue was fixed in 10% formaldehyde solution, embedded in paraffin and cut into sections. Serial sections (6 μm thick) from each block were stained with haematoxylin‐eosin, or incubated with the 6H4 monoclonal antibody recognizing PrP or the glial fibrillary acidic protein, using our previously described protocols (Castilla et al, 2005). Immunoreactions were developed using the peroxidase‐antiperoxidase method, following manufacturer's specifications. Antibody specificity was verified by absorption. Samples were visualized with a Zeiss microscope. The vacuolation profile was estimated by considering both number and size of vacuoles. Each analysed brain area was scored from 0 to 4 according to the extent of vacuolation in slides stained with haematoxylin‐eosin and visualized at a × 40 magnification. Samples were analysed blindly by two different people and the scores represent the average of the two determinations. The brain areas studied are the following: (1) dorsal medulla; (2) cerebellar grey matter; (3) superior colliculus; (4) lateral hypothalamus; (5) medial thalamus; (6) hippocampus; (7) occipital cortex and (8) cerebellar white matter.
The quantitative differences in the vacuolation profile obtained by histopathological analysis were assessed by two‐way ANOVA using brain areas and source of infectious material as the variables. Biochemical differences in PK susceptibility among strains were also analysed by two‐way ANOVA using the PK concentration and source of infectious material as the variables. In both cases, the data were analysed using the GraphPad Instat, version 3.05 software.
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
This research was supported in part by NIH grants NS0549173 and AG014359 to CS.
- Copyright © 2008 European Molecular Biology Organization